Use of Dexmedetomidine in Children Undergoing Cardiac Surgery

Bambino Gesù Hospital and Research Institute60 enrolled

Overview

The aim of the study is to evaluate the efficacy of dexmedetomidine in reducing the need for sedatives and analgesics in the immediate post-operative period in children who underwent surgical correction of complex congenital heart disease

The hypothesis the investigators want to verify is that the reduced administration of sedative drugs (opioids and benzodiazepines) in children undergoing cardiac surgery, reduces the side effects of the drugs themselves, such as respiratory depression (reduction of mechanical ventilation) and the onset of withdrawal symptoms while maintaining an adequate analgo-sedation. The study is an unblinded randomized controlled study. It will involve 60 children aged \> 1 and \< 24 months sedated and mechanically ventilated after corrective or palliative surgery of congenital heart disease on cardiopulmonary bypass with Aristotle score \> 8. Dexmedetomidine infusion will be started upon arrival in the CICU and continued until the time of discontinuation of morphine.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Deep Sedation

Interventions

dexmedetomidineDRUG

dexmedetomidine continous infusion 0.5 mcg/kg/h

Eligibility

Sex: ALLMin age: 1 MonthMax age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: age \< 24 months but \> 30 days, Aristotle score \>8, elective procedures in cardiopulmonary bypass - Exclusion Criteria: atrioventricular block prior to the start of infusion; vasoactive inotropic score on arrival to the CICU\>30; brain malformations orbone, muscle or neuromuscolar disease; pleural effusion or pneumothorax prior to the study; hepatic or renal failure \-

Locations (1)

Bambino Gesù Children's Hospital

Rome, Rome, Italy

Outcomes

Primary Outcomes

mechanical ventilation time

To evaluate the efficacy of dexmedetomidine, administered in combination with midazolam and morphine, in reducing the time of mechanical ventilation, due to lower consumption of opioids and hypnotics and subsequent reduction of respiratory depression

Time frame: participants will be followed for the duration of ICU stay, an expected average of 5 days

Secondary Outcomes

analgo-sedation level

efficient analgo-sedation guaranteed by the effectiveness of opioids and benzodiazepines with dexmedetomidine by using the Comfort scale and measuring the total amount of opioids and benzodiazepines received in the two groups.

Time frame: participants will be followed for the duration of ICU stay, an expected average of 5 days

withdrawal symptoms

onset of withdrawal symptoms due to abstinence from opioids and benzodiazepines evaluated using Sophia Observation withdrawal Symptoms scale in patients who received a continuous infusion for at least 72 hours

Time frame: participants will be followed for the duration of ICU stay, an expected average of 5 days

safety of dexmedetomidine infusion as a measure of systemic pressure decrease

assessment of the safety of dexmedetomidine infusion in light of hemodynamic changes induced by the drug (hypotension will be considered a reduction of \> 20% of the mean arterial pressure, bradycardia a reduction in heart rate \>20% of baseline

Time frame: participants will be followed for the duration of ICU stay, an expected average of 5 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.